Cart
sales@molnova.com
GW274150
CAS No. 210354-22-6
GW274150( GW-274150 | GW 274150 )
Catalog No. M13344 CAS No. 210354-22-6
GW274150 is a potent and highly selective inhibitor of iNOS with IC50 of 1.4 uM,
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 65 | In Stock |
|
| 10MG | 110 | In Stock |
|
| 25MG | 230 | In Stock |
|
| 50MG | 372 | In Stock |
|
| 100MG | 597 | In Stock |
|
| 500MG | 1675 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGW274150
-
NoteResearch use only, not for human use.
-
Brief DescriptionGW274150 is a potent and highly selective inhibitor of iNOS with IC50 of 1.4 uM,
-
DescriptionGW274150 is a potent and highly selective inhibitor of iNOS with IC50 of 1.4 uM, displays >200 fold selectivity over eNOS and nNOS (IC50>100 uM); attenuates the degree of chronic inflammation and tissue damage associated with collagen-induced arthritis in mice; significantly reduces serum urea, serum creatinine, AST, and NAG, reduces experimental renal ischemia/reperfusion injury.Rheumatoid Arthritis Phase 2 Discontinued.
-
In VitroGW274150 inhibits intracellular iNOS in J774 cells in a time-dependent manner, reaching IC50?values of 0.2 μM.GW274150?is >260-fold and 219-fold selective for iNOS against eNOS and nNOS in rat tissues, respectively. And it displays >100-fold and >80-fold for human iNOS against human eNOS and nNOS, respectively.
-
In VivoGW274150 is a long-acting (5 h half‐life in rats) iNOS inhibitor and is able to inhibit LPS‐mediated increase in plasma NO2-,?NO3-?levels 14 h after single intraperitoneal dose (ED50=3 mg/kg).GW274150 (intraperitoneal?injection; 2.5, 5, and 10 mg/kg; before carrageenan injection) reduces the degree of lung injury induced by carrageenan in a dose-related fashion. Oedema formation and PMNs infiltration in the pleural cavity are also significantly attenuated in a dose‐related manner in rats.GW274150 (oral adminstration; 30 mg/kg; twice daily; 7 days) leads to significant neuroprotection, However, it displays a bell-shaped neuroprotective profile, being ineffective at high doses in 6-OHDA rat model of Parkinson disease (PD). Animal Model:SD-rat Dosage:2.5, 5 and 10 mg/kg; single dose Administration:Intraperitoneal?injection 5 min before carrageenan injection Result:Exerted a protective role in an acute model of inflammation, carrageenan-induced lung injury.
-
SynonymsGW-274150 | GW 274150
-
PathwayImmunology/Inflammation
-
TargetNOS
-
RecptorNOS
-
Research AreaInflammation/Immunology
-
IndicationRheumatoid Arthritis
Chemical Information
-
CAS Number210354-22-6
-
Formula Weight219.3045
-
Molecular FormulaC8H17N3O2S
-
Purity>98% (HPLC)
-
SolubilityH2O: ≥ 62 mg/mL
-
SMILESCC(=N)NCCSCC[C@@H](C(=O)O)N
-
Chemical NameL-Homocysteine, S-[2-[(1-iminoethyl)amino]ethyl]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Young RJ, et al. Bioorg Med Chem Lett. 2000 Mar 20;10(6):597-600.
2. Cuzzocrea S, et al. Eur J Pharmacol. 2002 Oct 18;453(1):119-29.
3. McDonald MC, et al. J Physiol Pharmacol. 2002 Dec;53(4 Pt 1):555-69.
4. Chatterjee PK, et al. Kidney Int. 2003 Mar;63(3):853-65.
molnova catalog
related products
-
ETHYL CAFFEATE b
In vitro ECF suppressed the differentiation of naive CD4+ T cells into Th1. Furthermore ECF intensely blocked the transcriptional expression in interferon-γ-related signaling including IFN-γ T-bet STAT1 and STAT4.?
-
ASP 9853
A potent, orally active iNOS inhibitor that prevents dimerization of iNOS.
-
AR-C102222
AR-C102222 is a potent, selective iNOS inhibitor with IC50 of 35 nM, dislapys 3,000-fold and 20-fold selectivity over eNOS and nNOS respectively; reduces inflammation produced by the application of arachidonic acid to the ear, attenuates FCA-induced mechanical hyperalgesia, and attenuates acetic acid-induced writhing in mice.Rheumatoid ArthritisDiscontinued
